trial · primary record
Docetaxel
KRAS Gene Mutation
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 60 |
| Primary completion | 2027-03-03 |
| Primary endpoint | Response Rate (Confirmed and Unconfirmed Complete and Partial Responses) in All KRAS Mutant Participants |
| Registry ID | NCT02642042 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:33:08.714Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02642042
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.